OR WAIT null SECS
© 2024 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Making the Grade: The Importance of Using the Correct Excipient Grade in Drug Products
The emergence of mRNA vaccines and cell and gene therapies have pushed innovation in analytical methods.
Technical, regulatory, and personnel considerations characterize pharmaceutical compounding.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
Effective analytics will eliminate failures, deviations, and non-conformances.
Strategizing a PK/PD study approach in early phase development facilitates a successful clinical progression.
The Biosimilars Landscape
March 01, 2024
The partnership will allow for both companies to provide end-to-end biopharmaceutical manufacturing solutions.
CordenPharma’s new starter kits are designed to enable effective formulation in the development of mRNA-based therapeutics.
February 29, 2024
This discussion explores how the management and analysis of vast data generated by advanced analytical technologies are revolutionizing the drug discovery and development process within the biopharma industry.
February 28, 2024
The company is investing more than $250 million into its Bloomington, Ind. Manufacturing site.
Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.
Steffen Thirstrup, chief medical officer, EMA, emphasizes the importance of transparency in investigating potential safety issues of CAR-T therapies, while highlighting the need to balance regulatory diligence with maintaining trust within the community and among stakeholders.
February 27, 2024
CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen.
The agency has recommended granting marketing authorization to ALS treatment, Qalsody (tofersen), for adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.
February 23, 2024
Steffen Thirstrup, chief medical officer of the EMA, discusses manufacturing supply, drug shortages, commercial incentives, politics, and patient wellbeing.
February 21, 2024
FDA's Drug Safety Priorities FY23 describes the center’s key safety programs and activities involved in promoting and protecting public health.